Ricarda Herr

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7835828/publications.pdf

Version: 2024-02-01

687363 996975 1,089 15 13 15 h-index citations g-index papers 15 15 15 2269 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domains. Oncogene, 2020, 39, 814-832.	5.9	19
2	BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation. Oncogene, 2020, 39, 6053-6070.	5.9	19
3	BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines. Oncogene, 2018, 37, 1576-1593.	5.9	37
4	Discrete cytosolic macromolecular <scp>BRAF</scp> complexes exhibit distinct activities and composition. EMBO Journal, 2017, 36, 646-663.	7.8	52
5	Biglycan expression in the melanoma microenvironment promotes invasiveness via increased tissue stiffness inducing integrin- \hat{l}^21 expression. Oncotarget, 2017, 8, 42901-42916.	1.8	60
6	Phospho-proteomic analyses of B-Raf protein complexes reveal new regulatory principles. Oncotarget, 2016, 7, 26628-26652.	1.8	25
7	ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nature Communications, 2016, 7, 10498.	12.8	273
8	Global gene expression profiling analysis reveals reduction of stemness after B-RAF inhibition in colorectal cancer cell lines. Genomics Data, 2015, 4, 158-161.	1.3	2
9	BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?. Molecular and Cellular Oncology, 2015, 2, e1002709.	0.7	5
10	B-Raf Inhibitors Induce Epithelial Differentiation in <i>BRAF</i> -Mutant Colorectal Cancer Cells. Cancer Research, 2015, 75, 216-229.	0.9	43
11	EGFR-Targeted TRAIL and a Smac Mimetic Synergize to Overcome Apoptosis Resistance in KRAS Mutant Colorectal Cancer Cells. PLoS ONE, 2014, 9, e107165.	2.5	27
12	Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling. EMBO Journal, 2012, 31, 2629-2647.	7.8	110
13	Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Molecular Systems Biology, 2011, 7, 489.	7.2	172
14	Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. Acta Neuropathologica, 2011, 121, 763-774.	7.7	211
15	A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Communication and Signaling, 2011, 9, 17.	6.5	34